N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH

Rheumatology International

Volumn 28, Issue 7, 2008, Pages 657-660

  Simeoni, Sara ^a   Lippi, Giuseppe ^a   Puccetti, Antonio ^b   Montagnana, Martina ^a   Tinazzi, Elisa ^a   Prati, Daniele ^c   Corrocher, Roberto ^a   Lunardi, Claudio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Bosentan; NT proBNP; PAH; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIURETIC AGENT; OXYGEN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCLERODERMA; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 41849136869     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0510-7     Document Type: Article

References (14)

1. Siebold JR (2001) Scleroderma. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley's textbook of rheumatology, 6th edn. Saunders, Philadelphia, pp 1211-1240
2. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, Kahan A (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48:3503-3508
3. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J 324:1498-1500
4. Greig D, Castro P, Ferrada M, Lim J, López C, Braun S, Córdova S, Salazar M (2006) Brain natriuretic peptide in primary pulmonary hypertension. Rev Med Chil 134:299-304
5. Mukerjee D, Yap LB, Holmes AM, Nair D, Ayrton P, Black CM, Coghlan JG (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97:1230-1236
6. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG (2006) Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27:1485-1494
7. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
8. Karthikeyan VJ, Lip GY (2007) N-terminal pro-brain natriuretic peptide and coronary artery disease. Eur J Clin Invest 37:18-25
9. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ (2006) Bosentan in pulmonary arterial hypertension secondary to sclerodermia. J Rheumatol 33:61-68
10. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S (2006) Bosentan therapy of pulmonary arterial hypertension in connective tissue disease. Eur J Clin Invest 36:49-53
11. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926-932
12. Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, Bogossian H (2005) Effect of bosentan treatment on surrogate marker in pulmonary arterial hypertension. Curr Med Res Opin 21:907-911
13. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119-1123
14. Distler O, Pignone A (2006) Pulmonary arterial hypertension and rheumatic disease-from diagnosis to treatment. Rheumatology 45:22-25